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Introduction
Severe trauma and massive haemorrhage represent the 
leading cause of death and disability in patients under the 
age of 45 years in the developed world [1–5]. Because of 
the disproportionate incidence of trauma in younger peo-
ple, the burden to society is even bigger. Haemorrhage in 
the setting of trauma is responsible for 30–40 % of trauma 
mortality [5, 6], with 33–56 % of these deaths occurring 
in the pre-hospital period [5, 6], whilst one-third of these 
deaths occur in-hospital [7, 8]. Additionally, haemorrhage 
represents an important contributory factor for increased 
mortality of a different aetiology, particularly multi-organ 
failure and head injury [7, 9].
During the last decades, many advancements have been 
made in our understanding of the pathophysiology of 
trauma, the availability of diagnostic adjuncts and the intro-
duction of new resuscitation protocols [10]. Nevertheless, 
outcomes from massive haemorrhage remain poor, espe-
cially in the background of massive blood transfusion and 
significant coagulopathy [11].
The present review discusses the current literature 
with regard to the management of haemorrhage following 
trauma, with a special reference to the use of pharmaco-
logical adjuncts. Novel insights, concepts and treatment 
modalities are also discussed.
Pathophysiology of haemorrhage
The haemodynamic response triggered by trauma is bipha-
sic, with the systemic arterial pressure initially maintained, 
followed by a sudden decrease in the systemic arterial pres-
sure with increasing blood loss [12]. If the resuscitation is 
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not adequate, this haemodynamic redistribution can com-
promise the blood flow to vital organs, therefore further 
increasing mortality and morbidity [12].
Another significant factor contributing to increased mor-
tality and morbidity following trauma is that of acute coag-
ulopathy [11, 13, 14]. The development of coagulopathy 
is multifactorial and if not rapidly reversed, it results in a 
vicious circle often referred to as “acute traumatic coagu-
lopathy” or “acute coagulopathy of trauma shock” [11]. It 
is usually a combination of the inadequate tissue perfusion 
because of the resulting hypovolemia and the subsequent 
cell hypoxia, anaerobic respiration and metabolic acidosis, 
the thrombin–thrombomodulin-complex generation result-
ing from the tissue injury and the activation of anticoagu-
lant and fibrinolytic pathways [6, 14]. The resulting state 
of hyperfibrinolysis is believed to play a central role in the 
initial coagulopathy, since the maintenance of clot stability 
is equally important in clot formation [13]. Moreover, the 
associated hypothermia, which is very common in the trau-
matised and especially unconscious/sedated patient, leads 
to a reduced clotting enzymatic activity and a decreased 
platelet function, a process that further impairs coagulation 
[6].
Coagulopathy, acidosis and hypothermia are collec-
tively known as the “lethal triad” of trauma and their role 
in increasing trauma mortality and morbidity is well estab-
lished [6, 9, 11]. Understanding the pathophysiology of the 
lethal triad, as well as the importance of its rapid recogni-
tion, should serve as the cornerstone for the management of 
the bleeding trauma patient.
Blood management in trauma
Failure to promptly recognise bleeding and commence 
appropriate early management is the leading cause of pre-
ventable death following trauma [15]. A multidisciplinary 
approach aiming to the prompt recognition of shock due to 
haemorrhage following trauma (defined as loss of 20 % or 
more of the total blood loss) is of paramount importance, 
preferentially before the decompensation. The correct man-
agement, targeting at preventing or reversing any associated 
metabolic derangement, should be followed by timely inter-
ventions to control bleeding, restore tissue perfusion and 
achieve haemodynamic stability (Table 1) [5, 9, 14, 16].
In the pre-hospital setting, the adherence to the fun-
damental principles of Advanced Trauma Life Support 
(ATLS®) is emphasised, including the rapid transportation 
of patients to the hospital and limiting therapy to what is 
necessary to maintain adequate tissue perfusion, such as 
use of tourniquets to stop life threatening bleeding [14].
In-hospital, provided that ATLS® principles are adhered 
to, the source of bleeding should be rapidly identified. 
Multi-sliced computed tomography and ultrasound scans 
can be used as adjuncts to the clinical examination in the 
haemodynamically stable patient [14]. In the haemodynam-
ically unstable patient, early control of significant bleed-
ing in the abdomen and/or pelvis can be managed with 
surgical exploration, packing, angiographic embolisation 
and stabilisation of pelvic ring [14, 16]. Moreover, serial 
measurements of serum lactate and base deficit measure-
ments can be used for estimating/monitoring the extent of 
bleeding and shock, whereas post-traumatic coagulopathy 
should be monitored and promptly corrected [14]. Addi-
tionally, techniques/modalities which have been proved 
effective for resuscitating the trauma patients include: per-
missive hypotension (targeting a systolic blood pressure of 
80–90 mmHg, until any major bleeding has been stopped) 
and maintenance of minimally acceptable perfusion to pre-
vent vasoconstriction, dislodgement of the early thrombus 
and therefore increase of blood loss [4, 5, 14]; minimising 
the use of crystalloid intravenous fluids during resuscita-
tion, therefore minimising the effect of clotting factors dilu-
tion [4, 5, 14]; the use of crystalloid solutions with neutral 
pH, avoiding hyperchloremic metabolic acidosis associated 
with resuscitation with large-volume normal saline solu-
tions [4, 5]; the use of blood products including packed red 
blood cells (RBC), fresh frozen plasma (FFP) and platelets 
[4]; aggressive prevention of heat loss using heat blankets, 
blood warming devices and warm intravenous (IV) flu-
ids [4, 16]; and providing adequate analgesia to minimise 
movement and surges in blood pressure that can increase 
bleeding [16]. Most recently, attention has been shifted to 
the pathophysiology at a cellular level, with less sensitive 
parameters (systolic blood pressure and response to volume 
resuscitation) being de-emphasised [4].
In addition, in severe trauma, damage control surgery 
has been proven to be of vital importance [5]. According 
to this concept, a staged approach is followed with ini-
tial abbreviated surgical interventions to control bleeding, 
contamination and fracture stabilisation, which followed 
definitive surgical procedures when the patient conditions 
are improved [5]. Patients that should be considered for 
Table 1  Principles of blood management in trauma
1. Adherence to Advanced Trauma Life Support (ATLS®) principles
2. Rapid identification of the source of bleeding
3. Use of pelvic binders and tourniquets as indicated
4. Surgical exploration, packing, angiographic embolization and 
stabilisation of pelvic ring in the haemodynamically unstable 
patient
5. Correction of post-traumatic coagulopathy
6. Use of damage control surgery in severe trauma
7. Fluid resuscitation and transfusion of blood products as indicated
305Pharmacological adjuncts to stop bleeding: options and effectiveness
1 3
this approach are those in deep haemorrhagic shock with 
signs of ongoing bleeding and established coagulopathy, as 
well as patients with severe hypothermia, acidosis, major 
anatomic injuries that cannot be accessed, need for multi-
ple lengthy procedures or presence of major concomitant 
injuries [14].
Transfusion standards in trauma
It has been reported that more than 50 % of polytrauma 
patients are transfused, whilst in several developed coun-
tries over 15 % of these patients receive massive transfu-
sions (variably defined as transfusion of more than 10 
units of packed red blood cells or transfusion of more 
than 50 % of total blood volume in 24 h, or transfusion 
of more than 5 units in 4 h) [17, 18]. Balanced and early 
use of blood components including red blood cells, plate-
lets, plasma [fresh frozen plasma (FFP) or pathogen-inac-
tivated plasma], fibrinogen and cryoprecipitate has been 
reported to be effective in major bleeding [14, 19]. In addi-
tion, several risk factors have been identified to contribute 
to an increased blood loss in trauma patients, including 
use of anticoagulant medications, coagulation disorders, 
advanced age, use of a pneumatic tourniquet, critical ill-
ness and pre-existing anaemia [20–22]. Generally, a hae-
moglobin (Hb) target between 7 and 9 g/dl is considered to 
be satisfactory for achieving adequate oxygen delivery to 
the tissues [14].
Even though the safety of allogeneic blood product 
transfusion has considerably improved over the last dec-
ades, transfusion is still associated with significant mor-
bidity and mortality. Potential hazards of allogenic blood 
transfusion include the risk of infection (HIV, HBV, HCV) 
[23–25], non-infectious complications such as ABO incom-
patibility [26], haemolytic reactions, immunosuppression 
and even death [27, 28]. Historical transfusion risks such as 
transfusion errors (incorrect blood component transfused) 
and other acute transfusion reactions happen very rarely.
A recent meta-analysis on the risks associated with blood 
transfusion suggests that there is an association between 
increasing transfusion and mortality, sepsis, multi-organ 
system dysfunction and acute respiratory distress syndrome 
(ARDS) [17, 29]. Additionally, a Cochrane review reported 
that in-hospital mortality of patients receiving restrictive 
transfusion strategies was reduced, compared to patients 
managed with liberal transfusion strategies [25]. Therefore, 
the clinician should always balance the benefits of transfu-
sion against the possible risks, especially in patients who 
are not unstable, but had haemorrhage. Another facet that 
should be considered is that blood remains a scarce and 
costly resource; it has been previously reported that the cost 
of a unit of red blood cells to the National Health Service in 
2011 was £125 [23], whereas this cost is constantly rising.
Pharmacological strategies for blood management
A wide range of pharmacological agents has been used as 
adjunct in traditional techniques to obtain haemorrhagic 
control. These can generally be categorised into two major 
groups: topical (local) and systemic haemostatic agents.
Topical haemostatic agents
Topical haemostatic agents are particularly useful to arrest 
bleeding in areas where the anatomical access is difficult. 
Such agents include: collagen (acts by triggering platelet 
aggregation) [14]; gelatin-based products that are often com-
bined with a pro-coagulant substance (swell when in contact 
with blood reducing blood flow, whereas the pro-coagulant 
substance enhances haemostasis) [14]; cellulose-based prod-
ucts [14]; fibrin and synthetic glues or adhesives (have both 
haemostatic and sealant properties) [14]; and tranexamic 
acid (TXA) applied topically (its use in elective surgery is 
promising, but it is not yet popularised in trauma patients) 
[28]. As the use of the above agents is uncommon in the set-
ting of trauma, any further description of their action and 
properties will exceed the scope of this review. Polysaccha-
ride-based and inorganic haemostatics, on the other hand, 
have been successfully used in the development of haemo-
static dressings, applied mainly in military but also in Civil-
ian situations [6, 14, 30].
Haemostatic dressings
Haemostatic dressings include gauze style dressings 
enriched with powder or granular agents and have suc-
cessfully been used in the pre-hospital setting, effectively 
reducing morbidity and mortality through the early con-
trol of severe haemorrhage (within 2 min) [6, 13, 30]. The 
different mechanisms of action include: the concentra-
tion of clotting factors at the site of injury; formation of 
a mucoadhesive seal around the wound (chitosans); and 
by acting as pro-coagulants (i.e. by activating the coag-
ulation cascade or by providing exogenous clotting fac-
tors to the site of injury) [6, 13, 30]. Despite a number of 
preclinical animal studies and human case series, there is 
paucity of evidence that could provide an evidence base 
for using one type of haemostatic dressing over another. 
However, based on the current literature, Littlejohn et al. 
suggested that Combat Gauze is the safer and most effec-
tive in controlling haemorrhage [13]. Nevertheless, newer 
agents such as Celox Gauze and ChitoGauze are under 
306 M. Panteli et al.
1 3
investigation and preliminary studies about their use are 
promising [13].
Systemic haemostatic agents
The response to extensive tissue injury represents a com-
plex physiological process governed by several regulatory 
mechanisms, with haemostasis playing an important part 
of this process. As part of this response, the equilibrium 
is shifted and clot degradation (fibrinolysis) is stimulated, 
which in some cases may become pathological (hyper-
fibrinolysis) [31], an action that is considered to contribute 
to bleeding and coagulopathy [32]. Antifibrinolytic agents 
act by inhibiting the conversion of plasminogen to plas-
min, therefore decreasing the degree of fibrinolysis both in 
patients with normal or exaggerated fibrinolytic responses 
to tissue injury [28, 31]. The agents most commonly used 
include TXA, ε-aminocaproic acid and aprotinin.
Tranexamic acid
Tranexamic acid (TXA) is a synthetic lysine derivative, that 
acts as a competitive inhibitor of plasminogen activation, 
whereas at higher concentrations it acts as a non-compet-
itive inhibitor of plasmin [33]. It is believed that its main 
action is to improve coagulation trough stabilising the clot 
[19], but it has been reported that it also acts by inhibit-
ing plasmin-induced platelet activation, therefore preserv-
ing platelet function [28]. It has also been suggested that 
TXA may also act by reducing a broad spectrum of pro-
inflammatory effects of plasmin that may be associated to 
multi-organ system failure [19, 32, 34]. Another potential 
mechanism of TXA is that by reducing bleeding, it reduces 
the oxygen demand to the myocardium, simultaneously 
increasing oxygen supply [35].
Cumulative meta-analysis of the intravenous adminis-
tration of TXA shows reliable evidence that it significantly 
reduces the need for transfusion by 38 % in cardiac, ortho-
paedic, cranial and orthognathic, hepatic, and urological 
surgery [23]. Yet, some uncertainties and concerns about 
the effect of TXA on thromboembolic events and mortality 
are still present [23].
In the largest randomised controlled trial to date 
(CRASH-2), 20,211 patients with on-going significant 
haemorrhage or risk of significant haemorrhage were ran-
domised to receive TXA (1 g of TXA infused over 10 min, 
followed by an intravenous infusion of 1 g over 8 h) or pla-
cebo (0.9 % normal saline) [31]. Their results suggest that 
TXA reduced all-cause mortality (relative risk 0.91, 95 % 
CI 0·85–0·97) and risk of death because of bleeding (rela-
tive risk 0.85, 95 % CI 0.76–0.96) [31]. At the same time, 
no increased risk of non-fatal vascular occlusive events was 
recorded [31].
A further analysis of data from the same trial (CRASH-
2), combined with data from the UK Trauma and Audit 
Research Network, investigated the deaths that could be 
averted according to risk of mortality [35]. The authors 
suggested that by administrating TXA within 3 h from 
the traumatic event, the odds of death from bleeding was 
reduced by about 30 %, whereas the odds of thrombotic 
events was also reduced by about 30 %. [35]. Thereafter, 
they recommend that TXA should not be restricted to the 
most severely injured, but can be safely administered to a 
wide spectrum of patients with traumatic bleeding [35].
Nevertheless, an unexpected observation from the 
CRASH-2 trial was an increase in mortality because of 
bleeding in patients where TXA was administered more 
than 3 h after the injury; however, an increase in the all-
cause mortality was not evident in the same group of 
patients [31]. Even though this observation is not easy to 
interpret, possible explanations may include: the adverse 
effect of TXA in the established disseminated intravascular 
coagulation [23, 35]; the development of a pro-thrombotic 
state [23, 35]; reduced effectiveness of TXA when hypo-
thermia or acidosis is present [23, 35]; the possibility of 
a different effect of the TXA when administered at differ-
ent times following trauma [23, 35]; and the fact that these 
patients may have otherwise died from a non-bleeding 
cause [35].
Another retrospective study investigating the admin-
istration of TXA in combat injuries with active bleeding 
(MATTERs study) suggested that TXA is safe (not associ-
ated with an increased risk of thromboembolic events) and 
effective (a reduction of 6.5 % in absolute mortality was 
observed) [19]. The dosing regiment used in this study was 
an intravenous bolus of 1 g of TXA, repeated as felt indi-
cated by the managing physician [19]. Most importantly, 
the same group suggested that the effect of TXA was more 
beneficial in the patients with a higher injury severity, i.e. 
for the patients where a massive transfusion was deemed 
necessary (in this group, the absolute mortality was reduced 
by 13.7 %) [19].
It is also of note that both CRASH-2 and MATTERs 
studies failed to demonstrate any reduction in the need 
for transfusion [19, 31], in contrast to studies investigat-
ing the effect of TXA in elective surgery [23]. This may 
well reflect the complex equilibrium between the coagula-
tion, the fibrinolytic cascade and the physiology of trauma. 
Besides, since severely injured patients treated with TXA 
have a higher survival chance and also a higher incidence 
of transfusion compared to patients who die early follow-
ing trauma, this introduces a “survivor bias” [36].
In addition, an on-going trial (CRASH-3) investigates 
the safety and efficacy of TXA in patients with signifi-
cant traumatic brain injury [37]. The investigating group 
hypothesised that TXA counteracts the effect of tissue 
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plasminogen activator that plays an important role in the 
process of peri-lesional oedema, by blocking the conver-
sion of plasminogen to plasmin [37]. This hypothesis was 
based on the results of two previous randomized control 
trials [38, 39]. The first, the CRASH-2 Intracranial Bleed-
ing Study suggested a reduction in intracranial hemorrhage 
growth, fewer new focal ischaemic lesions on the CT scan 
and lower all-cause mortality in the patients receiving TXA 
[38]. Similarly, the second trial reported a reduction in 
hemorrhage growth and mortality in patients with intracra-
nial injury that received TXA [39].
With regard to the “ideal” loading and maintenance 
doses of TXA acid, this remains a subject of debate. In 
the literature, different regimens have been used by tri-
als ranging from 2.5 to 100 mg/kg for loading doses, and 
0.25–4 mg/kg/h delivered over 1–12 h for maintenance 
doses [31]. However, special attention should be given 
while administrating moderate or high doses of TXA (more 
than 24 mg/kg), as a dose-dependent increased seizure inci-
dence has been reported in open cardiac surgery [11, 40]. 
However, in the setting of trauma, calculations based on 
the weight of the patient may be time consuming and can 
potentially add a risk for errors. We therefore recommend 
the use of a fixed dose that is adequate to inhibit fibrinol-
ysis thus achieving haemostasis, but that is also safe in 
smaller patients.
Pre‑hospital use of tranexamic acid
The main aim of pre-hospital care remains the rapid trans-
portation of the bleeding patient to a facility for definitive 
care within the shortest amount of time, in order to stop 
bleeding and restore the circulating volume [5]. Some 
authors have suggested that, especially in the developed 
countries, TXA should be administered in the pre-hospital 
environment as this could lead to better outcomes through 
preventing full activation of fibrinolysis [14, 41, 42]. 
Besides, TXA can be safely stored in vehicles and can be 
simply administered to the polytraumatised patient [41, 42].
The above suggestion is based on the results of the two 
largest studies reporting on early administration of TXA 
[19, 34]. Following a subgroup analysis on death because 
of bleeding, the collaborators of CRASH-2 trial reported 
that treatment within 1 h from injury significantly reduced 
the risk of death (RR 0.68, 95 % CI 0.57–0.82), whereas 
treatment given between 1 and 3 h also reduced the risk of 
death (RR 0·79, 0.64–0.97) [34]. Thereafter, the odds ratio 
of TXA on death due to bleeding was calculated as low as 
0.61 (95 % CI 0.50–0.74), which is multiplied by a fac-
tor of 1.15 (95 % CI 1.08–1.23) for every hour that passes 
from the injury [34]. The MATTERs study group reported 
similar results, as all patients had the first dose of TXA 
administered within 1 h from injury [19].
ε‑Aminocaproic acid
ε-Aminocaproic acid is another synthetic lysine analogue, 
with a smaller half-life than TXA. The presence of subtle 
molecular variations between TXA and ε-aminocaproic 
acid, make ε-aminocaproic acid at least ten times less 
potent, therefore restricting its use in the cases that TXA is 
not available [14, 36].
Aprotinin
Aprotinin, a serine protease inhibitor, acts by directly inac-
tivating free plasmin, having little effect on bound plasmin 
[43, 44]. Even though aprotinin was reported to effectively 
reduce bleeding and transfusion requirements in major sur-
gery with a dose–response profile [44], its marketing was 
suspended in November 2007 questioning its safety [43]. 
Recently, the regulatory body has licensed aprotinin only 
for myocardial revascularisation [43]. Regardless of the 
presence of previous reports investigating its efficacy in the 
setting of trauma, this off-label use is now contraindicated 
[45–47].
Recombinant factor VIIa
Recombinant factor VIIa (rFVIIa) is a haemostatic agent 
approved for bleeding episodes in haemophilia patients 
[48–50]. Multiple studies have investigated its effectiveness 
in trauma, reporting decreased blood loss that did not, how-
ever, translate to better patient outcomes [48–50]. On the 
contrast, concerns about adverse thromboembolic events 
often resulting in serious morbidity and mortality were 
raised, whereas this off-label use was associated with an 
additional financial burden for hospitals [48]. Thereafter, 
the use of rFVIIa is not recommended in trauma patients 
[48–50].
Anticoagulated patients
With the rapid ageing of the population in most of the 
word, the number of anticoagulated patients is expected 
to continue growing [51–53]. As a result, the number of 
trauma patients using anticoagulant or antiplatelet agents is 
also expected to increase [51–53]. Previous reports suggest 
that pre-injury use of Warfarin represents an independent 
risk factor of mortality following trauma through altering 
bleeding and coagulation mechanism, whereas use of anti-
platelet agents is not associated with an increased mortality 
[51, 53, 54]. Yet, the use of warfarin or antiplatelet agents 
is associated with an increased risk of intra-cranial haemor-
rhage [51].
Based on these evidences, rapid treatment protocols may 
be considered, especially in the presence of intra-cranial 
308 M. Panteli et al.
1 3
head trauma where a prompt diagnosis is of paramount 
importance [55]. Anticoagulation reversal (INR of 1.5 or 
less) may include the use of Vitamin K, FFP, administration 
of prothrombin complex concentrates (contain a combina-
tion of factors II, VII, IX and X) [51, 55, 56], or a combi-
nation of the above that can be more effective [52]. Where 
there is a necessity of reversing the effects of antiplatelet 
agents, 10 units of platelets and/or desmopressin have been 
reported as effective [14, 57].
Overview
Severe trauma and massive haemorrhage remains the lead-
ing cause of death and disability in the young population. 
Even though much advancement has been made in the 
management of these patients with the introduction of com-
plex resuscitation protocols, the outcomes remain poor. The 
use of anti-fibrinolytic agents is one of the most promising 
interventions, but their benefits should be balanced with the 
risk of complications, especially thrombosis. Based on the 
available evidence and our experience, our recommenda-
tions are outlined in Table 2.
Following the publication of the CRASH-2 trial results, 
TXA has been incorporated into most trauma management 
protocols worldwide, both in the pre-hospital and hospital 
environment. The World Health Organization (WHO) has 
also included TXA into the List of Essential Medicines, 
whereas the National Institute for Health and Care Excel-
lence (NICE) is expected to publish a Clinical Guideline on 
the assessment and management of major trauma in Febru-
ary 2016 including the off-label use of TXA [58, 59].
The benefits of this easy-to-use molecule are also likely 
to be greater in the elderly population who have a higher 
baseline risk of death from haemorrhage and thromboem-
bolic events, an observation based on the reduction of the 
arterial events in this patient group [35]. Pererl et al. have 
developed and validated a prognostic model for risk of 
mortality based on clinical parameters such as age, Glas-
gow Coma Score (GCS), systolic blood pressure and geo-
graphic area [8]. This protocol could potentially be used as 
an additional tool for deciding whether or not to use life-
saving interventions such as TXA. In any case, the treating 
physician should use all the available information and their 
clinical judgment to the best interest of their patient.
Finally, it has been estimated that every year up to 
128,000 deaths worldwide can be averted if TXA is admin-
istered within 1 h from injury, whereas when administered 
within 3 h, up to 112,000 deaths can be averted [60]. This 
potential is more significant in low and middle income 
countries [60], whereas TXA is likely to be highly cost-
effective in any income setting as reflected by the life years 
saved [61].
Future directions
Pre-hospital care should be improved with TXA been incor-
porated in the management of bleeding trauma patients, 
whereas advanced trauma resuscitation protocols should 
be in place in order to reduce time to definitive haemor-
rhage control. Future research should aim into investigating 
trauma coagulopathy and the effect of interventions such as 
that of TXA. Finally, further pharmacokinetic and pharma-
codynamic studies are required to clarify the exact mecha-
nism of action of TXA, as well as the optimal doses in both 
the adult and paediatric populations.
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Table 2  Recommendations for use of pharmacological adjuncts
Administration/dose
Topical haemostatic agents
 Indications To arrest bleeding in areas where the anatomi-
cal access is difficult
 Recommendations Combat Gauze, Z-Medica, Wallingford, CT Pack gauze into wound and apply manual pressure for 3 min
Systemic haemostatic agents
 Indications To arrest heavy bleeding that cannot be con-
trolled with direct pressure or application of 
topical haemostatic agents
 Recommendations Tranexamic acid (TXA), Pfizer Dose: 1 g infused over 10 min, repeated as indicated
Use within 3 h from the traumatic event, but preferably within 1 h
Pre-hospital use is advocated
TXA should be included in every trauma resuscitation protocol
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